))
CAR T therapies: Engineering immune cells to treat cancer
Manage episode 357984997 series 3291201
Contenido proporcionado por CCRM. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente CCRM o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Featuring:
Dr. Joerg Krueger, Medical Director, CAR T-Cell Program, The Hospital for Sick Children.
Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine.
Our guests discuss the future of CAR T-cell therapies, in a conversation covering autologous and allogeneic CAR T therapies. Drs. Krueger and Levine share their thoughts on which of these two approaches is likely to pull ahead in the years to come, while acknowledging some of the challenges that will need to be overcome for each, including donor-to-donor variability. Also examined are the differences in adult and pediatric treatment options, along with the complexity involved in manufacturing CAR T cells. Recent advances in the area of solid tumours are highlighted, ending on a note that looks to the future of immunotherapy with warranted optimism.
Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.
19 episodios
Compartir
